In addition, another research showed reduced RRM1 expression increased sensitivity to gemcitabine in lung cancer cell lines, and found RRM1 expression in tumor is a major predictor of disease response to gemcitabine chemotherapy during a prospective phaseII clinical trial with NSCLC [8]. Here, RRM1 is linked to lung carcinoma.